Humanwell Healthcare announced that its holding subsidiary, Yichang Humanwell Pharmaceutical, has received the 'Drug Clinical Trial Approval Notice' for Brivaracetam tablets issued and approved by the National Medical Products Administration. Brivaracetam tablets are used for the treatment of partial seizures in patients aged one month and over. Currently, no other company in China has been approved to market this pharmaceutical.
人福医药：布立西坦片获药物临床试验批准
Humanwell Healthcare: Approval of clinical trials for Brivera tablets.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.